Conference call and webcast to be held at
4:30 p.m. EDT
NEW
HAVEN, Conn., May 4, 2023
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a
clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine ER) for the
treatment of chronic cough in adults with idiopathic pulmonary
fibrosis (IPF) and other chronic cough indications, and for the
treatment of prurigo nodularis, today announced that senior
management will host a conference call and live audio webcast
on Thursday, May 11, 2023, at 4:30 p.m. ET, to provide a
corporate update and review the Company's financial results for the
first quarter ended March 31,
2023.
![Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.) Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)](https://mma.prnewswire.com/media/1504281/Trevi_Therapeutics_Logo.jpg)
To participate in the live conference call by phone, please dial
(888) 317 6003 (domestic) or (412) 317 6061 (international) and
provide access code 0161285. A live audio webcast will be
accessible from the 'Investors & News' section on the Company's
website at www.TreviTherapeutics.com. An archived replay of
the webcast will also be available for 30 days on the Company's
website following the event.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing Haduvio, an investigational therapy in an oral
extended-release formulation of nalbuphine, for the treatment of
chronic cough in IPF and other chronic cough indications. Haduvio
is a mixed ĸ-opioid receptor agonist and µ-opioid receptor
antagonist that works both centrally and peripherally. The ĸ and µ
receptors are known critical mediators of cough. Parenteral
nalbuphine has been approved and marketed for over 20 years for the
treatment of acute pain indications and is not scheduled by the DEA
in the United States or by regulatory authorities in most
of Europe. Trevi intends to propose Haduvio as the trade name
for nalbuphine ER. Its safety and efficacy have not been evaluated
by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and
follow Trevi on Twitter and LinkedIn.
Investor Contact
Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-q1-2023-financial-results-and-provide-a-corporate-update-on-may-11-2023-301816535.html
SOURCE Trevi Therapeutics, Inc.